CMIC enters alliance with KineMed to identify drug candidates in Japanese market

By E. Janene Geiss

Philadelphia, May 24 - KineMed, Inc. said Wednesday that it has entered a strategic alliance with CMIC Co., Ltd., a contract research organization providing clinical development services in Asia.

The goal of the alliance is to identify compounds for indications discovery and potential joint development, according to a company news release.

Under the agreement, CMIC said it will seek compounds within Japanese pharmaceutical firms for indications discovery, which KineMed will undertake by applying its proprietary technologies (AquaTag and KineMarker). Upon successful discovery, KineMed said it may pursue collaborative development with a Japanese pharmaceutical partner or in-license agents for its own development programs.

CMIC said will have the option to become KineMed's partner and fund clinical development for the Japanese market through phase 2a.

KineMed is an Emeryville, Calif., drug development company using its proprietary biomarker technology (AquaTag and KineMarker) to measure the real-time activity of drugs in whole body systems.

CMIC is a Tokyo clinical research organization that has expanded its pharmaceutical development business to service the pharma-medical industry in Japan.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.